Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amcasertib + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Amcasertib + pembrolizumab is an experimental combination therapy under study in oncology. **Amcasertib** is a small molecule inhibitor of serine/threonine protein kinase 2 (also known as PBK/TOPK). **Pembrolizumab** is a monoclonal antibody that acts as a checkpoint inhibitor targeting programmed death 1 (PD-1) on T cells, restoring immune response against tumors. This drug combination is being explored for potential synergistic antitumor effects, particularly in advanced solid tumors and cancers that are refractory or resistant to monotherapy checkpoint inhibitors or kinase inhibitors. Amcasertib is developed by Eli Lilly, and pembrolizumab is developed by Merck.
- Other names
- amcasertib plus pembrolizumabLY-3214996 plus pembrolizumabLY3214996 plus pembrolizumabLY 3214996 plus pembrolizumabMK-3475 plus amcasertibMK3475 plus amcasertibMK 3475 plus amcasertib
02
Targets
NANOG (Nanog Homeobox)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on amcasertib + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amcasertib + pembrolizumab.